Ascendis Pharma A/S (ASND) Gains in Light Trading for June 23

Equities Staff  |

Shares of Ascendis Pharma A/S - ADR (NASDAQ:ASND) moved 6.70% up on June 23 to close at $91.47.

299,112 traded today. Their current average 30 day volume is 374,300 shares.

Ascendis Pharma A/S has moved 36.27% year-to-date in 2022.

The company is set to release earnings on 2022-08-10.

For technical charts, analysis, and more on Ascendis Pharma A/S visit the company profile.

About Ascendis Pharma A/S - ADR

Ascendis Pharma is applying its innovative TransCon technologies to build a leading, fully integrated biopharmaceutical company focused on making a meaningful difference in patients' lives. Guided by its core values of patients, science and passion, the company utilizes its TransCon technologies to create new and potentially best-in-class therapies.

To get more information on Ascendis Pharma A/S - ADR and to follow the company's latest updates, you can visit the company's profile page here: Ascendis Pharma A/S - ADR's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

Will Mining Stocks Fall Further?
3 Reasons To Be Optimistic About the Global Shipping Industry
The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks



Market Movers

Sponsored Financial Content